Angelman Syndrome and Prader-Willi Syndrome by Methylation
2005077
 
Consent Form RecommendedConsent Form Recommended
Additional Technical InformationAdditional Technical Information
Ordering Recommendation
Diagnostic testing for Angelman syndrome or Prader-Willi syndrome.
Mnemonic
AS PWS
Methodology
Methylation Sensitive Polymerase Chain Reaction/Fluorescence Monitoring
Performed
Mon, Thu
Reported
7-10 days
New York DOH Approval Status
This test is New York DOH approved.
Specimen Required
Patient Preparation
 
Collect
Lavender (EDTA), pink (K2EDTA), or yellow (ACD Solution A or B).  
Specimen Preparation
Transport 3 mL whole blood. (Min: 1.5 mL)  
Storage/Transport Temperature
Refrigerated.  
Unacceptable Conditions
 
Remarks
 
Stability
Ambient: 72 hours; Refrigerated: 1 week; Frozen: Unacceptable  
Reference Interval
By report
Interpretive Data
Background information: Angelman Syndrome and Prader-Willi Syndrome by Methylation:

Characteristics of Angelman Syndrome (AS):
Developmental delays by 6-12 months of age, seizures, microcephaly, movement or balance disorder, minimal or absent speech, and a distinctive behavioral phenotype, which includes a happy demeanor with frequent laughter, hand flapping, and excitability.
Prevalence
: 1 in 15,000.
Inheritance:
Varies, depending on the molecular genetic mechanism.
Cause
: Absence of maternal expression of the UBE3A gene.
Molecular Genetic Mechanisms
: Microdeletions in the AS/PWS critical region (68 percent), UBE3A mutations (11 percent), paternal uniparental disomy of chromosome 15 (7 percent), imprinting center defects (3 percent), unbalanced chromosome translocation (less than 1 percent), and unknown (10 percent).
Clinical Sensitivity:
78 percent.
Analytical Sensitivity and Specificity:
99 percent.
Methodology:
Bisulfite conversion and PCR amplification to detect methylation using melting curve analysis.
Limitations
: Molecular mechanisms not affecting methylation patterns that may result in AS will not be assessed. Diagnostic errors can occur due to rare sequence variations.

Characteristics of Prader-Willi Syndrome (PWS):
Neonatal hypotonia, hyperphagia, obesity, global developmental delay, mild intellectual disability, hypogonadism, and a distinctive behavioral phenotype, which includes temper tantrums, stubbornness, manipulative behavior, and obsessive-compulsive behavior.
Prevalence
: 1 in 15,000.
Inheritance:
Varies, depending on the molecular genetic mechanism.
Cause
: Absence of the paternally contributed PWS/AS critical region of chromosome 15q11.2-q13.
Molecular Genetic Mechanisms
: Microdeletions in the PWS/AS critical region (70-75 percent), maternal uniparental disomy of chromosome 15 (25-29 percent), imprinting center defect or balanced chromosome translocation (less than 1 percent).
Clinical Sensitivity:
Over 99 percent.
Analytical Sensitivity and Specificity:
99 percent.
Methodology:
Bisulfite conversion and PCR amplification to detect methylation using melting curve analysis.
Limitations
: Molecular mechanisms not affecting methylation patterns that may result in PWS will not be assessed. Diagnostic errors can occur due to rare sequence variations.

This test is performed pursuant to an agreement with Roche Molecular Systems, Inc.



Counseling and informed consent are recommended for genetic testing. Consent forms are available online at www.aruplab.com.

See Compliance Statement C: www.aruplab.com/CS
Note
CPT Code(s)
81331
Components
Component Test Code*Component Chart Name
2005078Angelman and Prader-Willi Specimen
2005079Angelman and Prader-Willi Result
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, contact interface support at interface.support@aruplab.com.
Cross References
  • Prader-Labhart-Willi Syndrome (Angelman Syndrome and Prader-Willi Syndrome by Methylation)
  • Prader-Willi Syndrome (Angelman Syndrome and Prader-Willi Syndrome by Methylation)